GDF-15 improves the predictive capacity of steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies
Open Access
- 12 October 2024
- journal article
- Published by Elsevier in Metabolism
- Vol. 163, 156047
Abstract
No abstract availableKeywords
Funding Information
- Massachusetts Life Sciences Center
- University Medical Centre Groningen (PPP-2019_023)
This publication has 41 references indexed in Scilit:
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002–2022)Clinical Nutrition, 2024
- The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter studyDiabetes Research and Clinical Practice, 2023
- Growth differentiation factor 15 (GDF-15) in kidney diseases2023
- Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complicationsHepatology International, 2022
- GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular diseaseBiomedicine & Pharmacotherapy, 2022
- Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexiaCytokine & Growth Factor Reviews, 2021
- Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK BiobankDigestive Diseases and Sciences, 2021
- Nonalcoholic Fatty Liver Disease and Recent Guideline UpdatesClinical Liver Disease, 2021
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015